The blockade of TLR2 signaling in different in vivo disease models [9,10] has been shown to prevent the development of insulin resistance, intimately associated with NAFLD pathogenesis [11]. Here, TLR2 is linked to metabolic dysfunction-associated steatotic liver disease.